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Abstract Transcatheter closure of patent ductus arterio-
sus (PDA) has been suggested to be the standard treatment
of PDA. Although, in general, the procedure shows a high
successful rate, outcomes may vary among pediatric car-
diology centers. To evaluate the effectiveness of tran-
scatheter closure of PDA in Cipto Mangunkusumo
Hospital, Jakarta, Indonesia, this was a retrospective study
on patients who underwent transcatheter closure of PDA in
Cipto Mangunkusumo Hospital during the period of
2002–2013. Hospital registry was reviewed and data about
patients’ characteristics, PDA severity, procedure, and
outcomes were retrieved. There were 298 patients, of
whom 90 were males, who underwent transcatheter closure
of PDA during the study period. Median age was 3.4 years
(1 months–18 years), and median body weight was 12
(3.6–59) kg. The diameter of PDA ranged from 1.1 to
15.4 mm with a median of 3.7 mm. Device could be de-
ployed in all patients, in which most were the Amplatzer
ductal occluder (69.8 %) and the remainders were coils.
Median fluoroscopy time was 15.4 (1.5–87) min, and
procedure time was 76 (30–200) min. Complete closure
was achieved in most patients (97.3 %), whereas device
migration occurred in a minority (0.3 %) of patients. No
major complication occurred during or after the procedure.
Transient anemia and bradycardia were found in 3.7 and
1.3 % patients, respectively. Most patients were discharged
from the hospital at 1 day after the procedure. Tran-
scatheter closure method is a safe and effective procedure
to close PDA.
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Introduction
Patent ductus arteriosus (PDA) constitutes 6–11 % of all
congenital defects [23]. It is estimated that PDA occurs
about 1 in 2500–5000 live births, and there are 4000 infants
with PDA born in Indonesia annually [6]. The incidence of
PDA is higher in preterm infants, which is about 8 per 1000
babies [6, 23]. PDA, especially the moderate and large
ones, often causes heart failures and growth disturbances in
children [23].
Transcatheter PDA closure has been routinely per-
formed in the last decade [2, 14, 16, 25, 26]. Since this
procedure is less invasive than surgical procedure, it has
become the treatment of choice for PDA [7]. Several fac-
tors have been suggested to determine the success of PDA
closure using these methods, such as the type of PDA
anatomy as suggested by Krichenko [15]. In Indonesia, the
first PDA transcatheter closure was done almost 16 years
ago; however, there has been no previous published study
evaluating the outcomes of transcatheter PDA closure
among Indonesian children [6]. The aim of this study was
to evaluate the outcomes of transcatheter closure of PDA in
Cipto Mangunkusumo Hospital, Jakarta, as a national re-
ferral hospital in Indonesia.
Methods
We included patients who underwent transcatheter closure
of PDA at Cipto Mangunkusumo Hospital (CMH) from
January 2002 until May 2013 and retrospectively analyzed
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their medical records, echocardiographic findings, hemo-
dynamic data, and early follow-up results. Selection crite-
ria for transcatheter closure of PDA were patients with
PDA, who the murmur was heard, had bounding pulse, and
their body weight C6 kg. All the PDA should be closed
except tiny PDA without bounding pulse and murmur.
Surgical ligation of PDA was indicated in neonates, tubular
type of PDA[5.5 mm or large PDA[12 mm.
The transcatheter closures of PDA were performed at the
catheterization laboratory using fluoroscopy guidance. All
patients underwent the procedure under general anesthesia.
After performing a hemodynamic study, we placed the ductal
occluder (Amplatzer ductal occluder-ADO) using a Mullin
delivery sheath, a delivery cable, and a loading catheter.
After the device was attached by screwing it to the tip of the
delivery cable, it was then inserted through the femoral vein
under the Mullin sheath to close the PDA. The device was
then released from the delivery cable after we confirmed that
it was placed correctly, resulting in no or smoky residual
shunt on angiography. On the other hand to deliver the coil,
we used a 4F multipurpose catheter and we cut the end of
catheter to throw out a side hole. The catheter was then in-
serted until its tip reaching the ascending aorta. A pusher
wire to open 1.5 or 2 loops of coil at descending aorta was
pushed. All systems were pulled until opened coils entering
the ampulla of PDA. The pusher wire and catheter were then
push and pull step-by-step up to open the proximal part of
coil. Finally, the part of coils was deployed at pulmonary
artery at 0.5 or 1 loop.
We obtained information regarding patient clinical
characteristics such as age, sex, and weight. The cardiac
catheterization data were also retrieved, including the size
of the PDA measured as the narrow diameter near the
branching point from the descending aorta seen in lateral-
view angiogram, type of PDA device, and fluoroscopy
time. Type of complications recorded included immediate
events, such as failure of device implantation, device em-
bolization, residual shunt, significant obstruction of aortic
arch and left pulmonary artery, infective endocarditis, and
massive blood loss. According to WHO 2011, anemia in
children of 6 months to 5 years was defined when the he-
moglobin level reached\11 g/dl. In children[5–11 years
was that when the hemoglobin level reached\12 g/dl, for
12–14 years if\12 g/dl, and for boys[15 years if\13 g/
dl, and for girls [15 years if \12 g/dl. All patients were
then followed up for any evidence of cardiac murmur.
Follow-up echocardiography was performed using Philips
Sonos 4500 machine to evaluate residual PDA, left pul-
monary artery stenosis, and descending aorta stenosis.
Clinical characteristics, type of occluder device, and
immediate results/complications were described as mean,
median, or proportion as appropriate. Statistical analyses
were performed using SPSS statistics 17.0 for Windows.
Results
A total of 298 patients who underwent the transcatheter
closure procedure between 2002 and May 2013 were en-
rolled. The baseline characteristics are described in
Table 1. There were more females than males with wide
ranges of age, body weight, as well as PDA diameter.
Successful device deployment was achieved in all patients.
Most subjects have their PDA occluded using the Am-
platzer device (Table 1).
Outcomes of catheterization and intervention are de-
picted in Table 2. The procedure time varied widely with a
median of approximately 1 h. Sizes of the Gianturco coils
were 5 cm 9 5 mm and 5 cm 9 8 mm. Sizes of ADO I
ranged from 4 to 14 mm with the median of 6 mm. Most
(97 %) patients achieved complete closure and only one
who had significant residual shunt. Device migration was
found in one patient with a very large PDA (15.4 mm) who
weighed only 11 kg. We initially attempted to close the
PDA by a 12-size device.
Among our subjects, we did not find any complication
related to vascular access, hemolysis, and massive blood
loss (Table 2). Only minority of patients experienced
anemia (3.7 %) or transient bradycardia (1.3 %). No death
occurred in this study.
Discussion
In this study, we reported the largest case series of tran-
scatheter closure of PDA in Indonesia. The number of fe-
males was more than males, which is similar to findings
previously reported in the literature [23]. However, the
transcatheter technique to close PDA is not different be-
tween genders. Overall, we found that PDA transcatheter
closure has a high success rate and rarely causes major
complication in most of the cases.
The first transcatheter closure of PDA was performed by
Portsman et al. [20] in late 1960s. This initial work was
continued by Rashkind et al. [21] in late 1970s, after which
it is performed and developed worldwide [2, 14, 16, 25,
26]. When a diagnosis of PDA is established, closure of
PDA is recommended, either by surgery [12] or tran-
scatheter closure [2, 14, 16, 25, 26], to avoid pulmonary
overflow and prevent infective endocarditis.
Previous studies have shown that transcatheter closure
of PDA is quite an established technique with no reported
mortality and low morbidity. A retrospective case series of
1808 patients undergoing transcatheter closure of PDA
showed that overall PDA closure rate was 94 %, and the
rate of major average events were 1.5 % [11]. Only few
minor complications were found. The evidence of effec-
tivity and safety of transcatheter PDA closure has been
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shown in another studies as well [2, 14]. Despite our short
follow-up, we also found that the transcatheter closure of
PDA is effective and save. There were minimal intrapro-
cedure complications, which were anemia and transient
bradycardia.
Before the era of transcatheter method, PDA was ligated
surgically. Gross and Hubbard [12] performed the first
successful ligation of PDA in late 1930s. Since then, li-
gation of PDA has been the treatment of choice for PDA
closures until transcatheter procedures were introduced.
Recently, PDA ligation reserved only for neonatal PDA
that does not respond to medical treatment or has a di-
ameter more than 14 mm [6]. In our study, the youngest
patient aged 1 month with a body weight of 3.6 kg. Ac-
tually, this patient previously had undergone surgical li-
gation but had residual shunt. Considering the small size of
his residual PDA, we decided to close it transcatheterly
using a Gianturco coil, which is relatively cheaper com-
pared to other devices. Our policy is to close the PDA using
a coil if the diameter is\3 mm, otherwise it is closed using
a ductal occluder [6]. In our series, we mostly used ADO
and only used coil in approximately 5 % of patients. Ac-
cording to the literature [2, 14, 16, 25, 26], there are some
advantages of using ADO over coil. First, the shape of
ADO is more appropriate to close PDA in order to avoid
residual shunt. Second, the ADO device can be retrieved in
case the device does not fit the PDA. Besides that, the ADO
device is also less likely to embolize than the coil.
All the PDAs in this series were closed using ADO I and
Gianturco coils. Gianturco coils were used to close PDA
\3 mm. We used transvenous coil closure approach in all
16 cases. Coils were also used for closing residual surgical
ligation of PDA. In these residual PDA ligation, we could
not use ADO I because the delivery catheter and sheath
could not pass the residual PDA ligation.
We used ADO II to close tubular PDA \5.5 mm be-
cause the readily available ADO II could only be used to
close PDA up to 5.5 mm, and in this series, we did not have
the case. So far, we used ADO II to close small per-
imembranous VSD, small muscular VSD, and doubly
committed sub-arterial (DCSA) VSD. Closing these DCSA
VSD using ADO II had potential advantage since it was
soft and flexible and did not interfere aortic valve activity.
In addition, additional size (AS) of ADO II was not
available in our institution. According to the readily
available recommendation for closing PDA using ADO I,
the minimal body weight is 6 kg. However, in our expe-
rience, we successfully closed PDA in patients\6 kg.
In our study, the majority of patients achieved complete
closure, and the rate of residual significant shunt was only
\1 %. These results were comparable to other previous
studies [13, 16]. Due to this small number of subjects with
residual shunt, we were not able to statistically evaluate
factors related to unsuccessful procedure. In most cases, we
only found a smoky residual shunt using coils or ADO I. In
one case, we found a small residual shunt that finally dis-
appeared in a 6-month period of follow-up.
We experienced aortic protrusion of the device, that is a
possible complication using ADO I in small children, but it
did not influence the pressure gradient between ascending
and descending aorta. In addition, there was one case of
embolization of device to the right pulmonary artery; it was
not easy to catch that device. This might because the
Table 1 Characteristics of the
patients (n = 298)
ADO Amplatzer duct occluder




Age (range) 3.4 years (1 month–18 years)
Body weight, median (range), kg 12 (3.6–59)
Diameter of the duct, median (range), mm 3.7 (1.1–15.4)
Type of device used
ADO I 282 94.6
Gianturco coil 16 5.4
Table 2 Outcomes of catheterization and intervention (n = 298)
Variable Number %
Procedure time, median (range), min 76 (30–200)
Fluoroscopy time, median (range), min 15.4 (1.5–87)
Immediate results
Complete closure 290 97.3
Small residual shunt 6 2
Moderate residual shunt 1 0.3





Hospital stay, median (range) days 1 (1–5)
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screwed pin of ADO I was inside the device. We used two
snares to catch the device. First snare was used to snare the
body of device so the screwed pin protruded out and the
second snare then easily captured the device.
In order to monitor heart failure and therapy, some
studies reported that B-type natriuretic peptide (BNP)
hormone may be useful [1, 4, 5, 9, 10, 17, 18]. It has been
recognized that BNP level is higher in children with PDA.
This hormone is released by myocyte cells as a response to
left atrial and left ventricular dilatation. PDA causes a
proportion of blood flowing from the aorta to the pul-
monary artery, which leads to excessive blood flow in the
pulmonary circulation [6, 23]. This excessive blood flow
then drains into the left atrium and left ventricle leading
chamber dilatation and left heart failure. In our previous
study [9], we found that after PDA closure, the mean BNP
level significantly decreased from 58 to 28 pg/ml
(p = 0.001), which was more prominent in the first month
after PDA closure. In that study, which involved 23 chil-
dren, seven of nine children with a high BNP level before
the PDA closure showed a normal BNP level at 6-month
follow-up. However, in this study, we did not evaluate the
BNP level in our subjects since this examination was not
conducted routinely in our setting. The transcatheter clo-
sure of PDA can be done using either Amplatzer duct oc-
cluder (ADO I) or Gianturco coil. The ADO is made from
an alloy called Nitinol wire mesh, containing 55 % nickel
and 45 % titanium. There is still a controversy about the
effects of nickel contained in this device. Concerns arise
since this alloy can lead to intoxication through blood
stream and can induce cancer [24]. Ries et al. [22] reported
that nickel contained in the device used in the transcatheter
closure of atrial septal defect can be released to the blood
stream and lead to significant elevation of blood nickel
level compared to the level before the procedure. In our
previous study [8], we found that the blood nickel level
observed at six month after the ADO procedures did not
increased significantly, and the concerns about nickel re-
leased to the blood stream were not proven. This finding
was consistent with previous findings of Coe et al. [3]. In
this study, we also did not measure the blood nickel level
since it was not performed routinely in our procedure.
Important factors determining the success of a proce-
dure are vascular accessibility, availability of devices,
morphology of ductus, and imaging modality [26]. Vas-
cular accessibility is important as thrombosis may be
formed in femoral vessels due to the breakage of the
endothel. The morphology of the ductus and measure-
ments of its size should be done before the procedure to
minimize procedural risks and to select appropriate de-
vice. In these procedures, we used femoral artery and vein
to insert the sheath. We did not find any thrombosis in
our series.
Imaging modality is also an important factor, especially
in small children, where portable imaging modality may be
beneficial in performing bedside procedure [19]. There are
many advantages of transcatheter closure of PDA com-
pared to surgical ligation procedures [7]. The procedure is
less invasive, leaving no surgical scar and results in shorter
hospitalization as well as lower cost. In general, the length
of hospital stay in our study is 1 day as reported in other
studies. The success rate is also comparable to surgical
ligation [7]. However, the surgical ligation is still indicated
in large PDA [6].
In conclusion, transcatheter closure of PDA is a safe and
effective method to close PDA in children.
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